Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity
- Biophytis forms new Scientific Advisory Board
- IND to be filed with FDA soon
- Focus on developing BIO101 for obesity with GLP1-RA
Biophytis / Key word(s): Miscellaneous
Biophytis announces new Scientific Advisory Board
|
This Scientific Advisory Board will be composed of a few worldwide medical experts in the field of obesity, including Professor Dennis Villareal from the USA and Professor Francisco Guarner from Spain. The OBA SAB will guide the company to develop BIO101 (20-hydroxyecdysone) in obesity, in combination with GLP1-RA, and will actively work towards the finalization of the OBA Phase 2 clinical study design. Biophytis plans to file for an Investigational New Drug (IND) application to start the OBA Phase 2 clinical study in the USA with FDA in the coming weeks.
Prof. Dennis Villareal, Professor of Medicine-Endocrinology, Diabetes and Metabolism at Baylor College of Medicine Houston, Texas, comments: " GLP-1 agonists have proven to be effective in body weight loss but they also may lead to potential loss of muscle mass in adults with obesity. Therefore, there is an urgent unmet medical need for a clinical study to evaluate whether a drug targeting muscle function such as BIO101 (20-hydroxyecdysone) can effectively preserve muscle strength during weight-loss therapy of patients with obesity treated with GLP1 RA."